Bayer AG (BAYN) Receives Consensus Rating of “Buy” from Brokerages
Bayer AG (FRA:BAYN) has received an average recommendation of “Buy” from the twenty-three research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is €118.90 ($146.80).
A number of research analysts have commented on the company. Commerzbank set a €124.00 ($153.09) price target on Bayer and gave the company a “buy” rating in a research report on Wednesday, February 28th. Baader Bank set a €140.00 ($172.84) target price on Bayer and gave the stock a “buy” rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. reiterated a “buy” rating and set a target price on shares of Bayer in a report on Wednesday, February 28th. Goldman Sachs Group set a €125.00 ($154.32) target price on Bayer and gave the stock a “buy” rating in a report on Wednesday, February 28th. Finally, Sanford C. Bernstein set a €129.00 ($159.26) target price on Bayer and gave the stock a “buy” rating in a report on Wednesday, February 28th.
Bayer (FRA:BAYN) traded up €1.93 ($2.38) on Wednesday, reaching €94.62 ($116.81). The company’s stock had a trading volume of 2,430,766 shares. The company has a market cap of $76,100.00 and a price-to-earnings ratio of 25.44. Bayer has a fifty-two week low of €91.58 ($113.06) and a fifty-two week high of €123.82 ($152.86).
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.